



Therapies for Overseas Patients

Copyright 2020, 2021 Vamos Biotech (Shanghai), CO, LTD

TABLE OF CONTENT



1. *Available Cancer Immunotherapies*
2. *About Vamos Biotech*
3. *Work-Flow*
4. *Clinical Treatment Flow*
5. *Check list*
6. *Support Tool*

Available T-Cell Therapies

	CAR-T cell therapies	Indications
1	CD-19/22/BAFF-R	Paed & Adult: r/r B cell-Acute Lymphoblastic Leukemia (ALL)
3	CD-19/79b	r/r Non-Hodgkin Lymphomas (NHL): DLBCL
4	BCMA	Multiple Myelomas
5	CD-30	Hodgkin Lymphoma Hodgkin淋巴瘤; Anaplastic Large cell Lymphoma
6	IL13R α 2 CAR-T	r/r Glioblastoma multiforme (Brain/GBM)
7	Claudin 18.2	Gastric Cancer, Pancreatic Cancer
8	Mesothelin	Mesothelioma, Pancreatic, Ovarian, Colorectal, Peritoneal, Fallopian tube, Breast, Lung Cancer
9	GPC3	Liver Cancer, Pancreatic Cancer, Colorectal Cancer

	T Cell Therapies	Indications
1	scFv ICI	Variety of advanced cancers, such as NSCLC, uterine CA, melanoma, breast CA, etc
2	HPV TCR-T	HPV associated cancers (cervical, Vulvar, Vaginal, Penile, Anal, Oropharyngeal & Larynx) Human papilloma virus (HPV)
3	TAA-T	Variety of advanced cancers, such as Melanoma, Neuroblastoma Wilms Tumor, Sarcomas (Rhabdomyo, soft tissue, Ewing, Osteo)
4	TIL	Variety of advanced cancers – personalized

SAVING LIVES



*Every year, the number of people diagnosed with cancer is increasing. More and more cases of patients dying from cancer reported, a lot of them cannot make it due to unaffordable cost of cancer treatment. Cancer treatments are just too expensive, making it impossible for a lot of unfortunate patients to afford it. This is the main reason **Vamos Biotech** engaged in life-cell therapies.*

The original intention to save the unfortunate and needy patients had always been our ultimate goal. It is our dream to drive, to strive, in helping more patients in SE Asia and ultimately the world, to receive affordable treatment and thus, to contribute back to society.

BEST IN CLASS



Pioneer

Most Innovative and latest technology



First to Market

Most advanced and commercially available




Proven

Clinical Trial Completed, Approved



Most Affordable

Easy to access, most cost effective in the industry




ONE-STOP SERVICE CENTER



- *Pre-Treatment; patients screening with data protection*
- *Treatment; admission & T-cell based immunotherapy*
- *Post Treatment; PET-CT scanning & follow up*

MAIN BENEFITS

- *Education & training of foreign doctors through observation of real cases.*
- *Local experts with real hands-on experiences in handling large number of patients.*
- *Regional & International Networking*



COMPASSIONATE USE




Expanded access is a potential pathway for a patient with an immediately life-threatening condition, or serious disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside the clinical trials when no comparable or satisfactory alternative therapy options are available.

Compassionate use is a treatment option that allows the use of an unauthorized medicine.

Under strict conditions, products in development can be made available to groups of patients who have a disease with no satisfactory authorized therapies and who cannot enter clinical trials.


PROCESS FLOW

CAR T-cell Therapy




BASIC PRINCIPLES

basic principles of adoptive cellular therapies (ACT)



Recognizing Cancer



TREATMENTS IN MALAYSIA

- **Referral of Overseas Patients**
Patients are referred to Vamos by Agents or Partner Hospitals/Oncologists from overseas.
- **Pre-Treatment**
Medical Reports are provided to our medical teams in Malaysia.
- **Treatment**
The treatment is performed in one of the private hospitals in Malaysia by renowned experts.



OVERSEAS TREATMENTS




- **Pre-Treatment**
Patients are selected for treatment in our partner hospitals, and apheresis is performed.
- **Preparation of CAR-T**
The PBMC are collected from the partner hospital by Vamos, shipped to Malaysia for processing. Once the CAR-T are prepared and cryopreserved, the infusion bag for therapy is sent and delivered to the overseas hospital for treatment.
- **Treatment**
The treatment and the post-treatments are performed in one of our partner hospitals.

WORKFLOW


<i>Suitable patients for cancer immunotherapy after baseline screening by in-house physician/Hemo/Onco (CPI, CAR-T, Allo-T, TCR-T, TAA-T, TIL)</i>
<i>Obtain patient's consent & arrangement for Apheresis</i>
<i>Collection of PBMC by Vamos, isolation, and cryopreservation at a local laboratory.</i>
<i>Shipping of the PBMC to Vamos laboratory in Malaysia via World Courier.</i>
<i>Pre-treatment</i>
<i>Treatment (infusion of the immunotherapy cells)</i>
<i>End of treatment imaging (CT/MRI/PET-CT) or Biopsy (month 3 & 6 1st dose) for efficacy assessment</i>
<i>Post Infusion patient monitoring & manage SE</i>

CLINICAL TREATMENT FLOW



Before the infusion of the CAR-T cells into the patients' body, all patients receive a low dose of chemotherapy to lower the tumor burden and eliminate one part of the lymphocytes, this treatment will benefit the side effects control.

MANAGING THE SIDE EFFECTS



MANAGING THE SIDE EFFECTS

Characteristics of CAR- and TCR-engineered T cells.

CAR T cells	TCR T cells
Signal amplification from synthetic biology: 200 targets can trigger CAR T cells (57)	Sensitive signal amplification derived by evolution of the TCR
Avidity-controllable	Low-avidity, unless engineered (58)
CAR targets surface structures: proteins, glycans	TCR targets intracellular proteome
MHC-independent recognition of tumor targets	Requires MHC class I expression and HLA matching on tumor.
At least decade-long persistence (59)	Lifelong persistence
Serial killers of tumor cells (60)	Serial killers of tumor cells (60)
Cytokine release syndrome more severe than with TCR-based therapy	Off-tumor toxicity difficult to predict (7)

Strategies to overcome current clinical challenges associated with CAR T cell therapies.


Issue	Strategy	Expected outcome
Cytokine release syndrome	Tocilizumab, siltuximab, JAK kinase inhibitors, corticosteroids	Blocking IL-6 effects rapidly reverses fevers, hypotension, and hypoxia
Development of anti-CAR idiotypic antibodies to murine scFvs	Use humanized scFv	Longer persistence of CAR T cells
Lack of persistence of CAR T cells	Understand mechanisms of signaling domains that impart increased longevity (63); use sorted memory or stem cells	Long-term persistence of CAR T cells when desired by clinical situation
Relapse owing to loss of CD19 epitope	Target CD22 and CD19	Combinatorial surface targeting prevents escape

CHECK LIST (DOCUMENTS)



- **Treatment History**
All documents describing the treatment history must be in order.
- **Biopsy or Surgical Specimen HPE**
Try to compile all-in-one PDF file.
- **Imaging (CT/PET-CT)**
Take only the latest imaging.
- **Biomarker tests**
Include IPT for leukemia (if applicable)
- **Genomic Tests**
If available.

SUPPORT TOOLS




Detailing Add

To share with the specialist who requires the trial summary



LBM (pts)

Patient's stories.



Physician Flip Chart

In calendar form that allow staffs to share with patients



Clinical Papers

Mainly to share with specialists or patients

Pediatric & Adult ALL:

- Maude et al, 2014
- Maude et al, 2018
- Tan et al, IACH 2018, poster
- Cao et al, 2019

Multiple Myeloma


- Yan et al, 2019
- Brudno et al, 2018

Glioblastoma


- Brown et al, 201

MARKETING TOOLS

Detailing Add



Physician's Flip Chart



LBM



Clinical Papers

Pediatric & Adult ALL:

- Maude et al, 2014
- Maude et al, 2018
- Tan et al, IACH 2018, poster
- Cao et al, 2019

Multiple Myeloma

- Yan et al, 2019
- Brudno et al, 2018

Glioblastoma

- Brown et al, 2011

Why Vamos?



Our Focus

We invent and produce new technology and new substances for treatment of cancers, viral infections, antibiotic resistant bacterial infections, and other incurable diseases.

Our Results

Our products achieve results in treatments of many incurable diseases for which treatments are not available or no results can be reached.

Our Prices

The costs of our cancer immunotherapies are the lowest in the industry and significantly lower compared to any other competitor, while at the same time, our results are second to none.

THANK YOU



VAMOS BIOTECH (SHANGHAI) CO., LTD

2F, Building #5, Lin Gang Fengxian Industrial Park,
1800 Xin Yang Road, Feng Xian District,
Shanghai 201413, P.R. China

Tel: +86 213 712 3366

Email: info@vamos-biotech.com

www.vamos-biotech.com

